uniQure N.V., a gene therapy company focused on Huntington's disease and other genetic disorders, disclosed in its Form 10-Q filed on July 29, 2026, that it has agreed to a preliminary settlement in a securities class action lawsuit. The company also updated investors on the status of two related shareholder derivative lawsuits that remain pending.
Securities Class Action Settlement
The class action litigation, originally filed in 2024, consolidated multiple lawsuits brought on behalf of investors who purchased uniQure securities between May 2021 and December 2023. The plaintiffs alleged that the company made materially false and misleading statements regarding the safety and efficacy of its lead gene therapy candidate, AMT-130, for the treatment of Huntington's disease.
According to the filing, the parties reached a preliminary agreement to settle the class action in June 2026. The settlement, which remains subject to court approval, will be funded primarily by uniQure's insurance carriers. The company stated that the settlement amount is not expected to have a material adverse effect on its financial condition or results of operations. The specific settlement figure was not disclosed in the quarterly report.
Ongoing Derivative Litigation
Separately, uniQure continues to face two shareholder derivative lawsuits filed in 2025. These actions, brought nominally on behalf of the company, name certain current and former officers and directors as defendants. The derivative complaints largely echo the allegations in the securities class action, claiming that the individual defendants breached their fiduciary duties by failing to oversee the company's clinical trial disclosures and public statements adequately.
The company noted in the filing that these derivative matters are still in their early procedural stages and that it intends to defend against them vigorously. No trial dates have been set for either derivative case.
Financial Context
The litigation disclosures arrived in a quarterly report that showed uniQure's financial position has strengthened considerably. The company reported cash, cash equivalents, and current investment securities totaling $810.3 million as of June 30, 2026, up from $622.5 million at the end of 2025, largely due to a follow-on public offering completed earlier in the year. The net loss for the second quarter widened to $81.1 million, compared to $37.7 million in the same period a year earlier, driven in part by a $16.0 million non-operating loss related to changes in the fair value of pre-funded warrant liabilities.
The company is advancing AMT-130 toward potential regulatory submissions, having announced plans to file a Biologics License Application with the U.S. Food and Drug Administration and a Marketing Authorization Application with the United Kingdom's Medicines and Healthcare products Regulatory Agency. The resolution of the securities class action removes a layer of legal uncertainty as uniQure approaches these regulatory milestones.